Angelo Paci
Angelo Paci
Verified email at
Cited by
Cited by
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 MutationsAG-221 Therapy for IDH2-Mutant AML
K Yen, J Travins, F Wang, MD David, E Artin, K Straley, A Padyana, ...
Cancer discovery 7 (5), 478-493, 2017
Review of therapeutic drug monitoring of anticancer drugs part two–targeted therapies
N Widmer, C Bardin, E Chatelut, A Paci, J Beijnen, D Levêque, G Veal, ...
European journal of cancer 50 (12), 2020-2036, 2014
Review of therapeutic drug monitoring of anticancer drugs part 1–cytotoxics
A Paci, G Veal, C Bardin, D Levêque, N Widmer, J Beijnen, A Astier, ...
European journal of cancer 50 (12), 2010-2019, 2014
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
P Liu, L Zhao, J Pol, S Levesque, A Petrazzuolo, C Pfirschke, C Engblom, ...
Nature communications 10 (1), 1486, 2019
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer
C Coutzac, JM Jouniaux, A Paci, J Schmidt, D Mallardo, A Seck, ...
Nature communications 11 (1), 2168, 2020
Vemurafenib in pediatric patients with BRAFV600E mutated high‐grade gliomas
F Bautista, A Paci, V Minard‐Colin, C Dufour, J Grill, L Lacroix, P Varlet, ...
Pediatric blood & cancer 61 (6), 1101-1103, 2014
Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis
D Elias, A El Otmany, M Bonnay, A Paci, M Ducreux, S Antoun, P Lasser, ...
Oncology 63 (4), 346-352, 2002
Therapeutic drug monitoring in cancer–are we missing a trick?
C Bardin, G Veal, A Paci, E Chatelut, A Astier, D Levêque, N Widmer, ...
European journal of cancer 50 (12), 2005-2009, 2014
Personalizing busulfan-based conditioning: considerations from the american society for blood and marrow transplantation practice guidelines committee
J Palmer, JS McCune, MA Perales, D Marks, J Bubalo, M Mohty, ...
Biology of Blood and Marrow Transplantation 22 (11), 1915-1925, 2016
Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo …
MH Massicotte, I Borget, S Broutin, VE Baracos, S Leboulleux, E Baudin, ...
The Journal of Clinical Endocrinology & Metabolism 98 (6), 2401-2408, 2013
Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice
LH Reddy, H Khoury, A Paci, A Deroussent, H Ferreira, C Dubernet, ...
Drug metabolism and disposition 36 (8), 1570-1577, 2008
Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells
S Hescot, A Slama, A Lombes, A Paci, H Remy, S Leboulleux, ...
Oxazaphosphorines: new therapeutic strategies for an old class of drugs
B Giraud, G Hebert, A Deroussent, GJ Veal, G Vassal, A Paci
Expert opinion on drug metabolism & toxicology 6 (8), 919-938, 2010
The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development
F Lemonnier, RA Cairns, S Inoue, WY Li, A Dupuy, S Broutin, N Martin, ...
Proceedings of the National Academy of Sciences 113 (52), 15084-15089, 2016
Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric …
A Paci, G Vassal, D Moshous, JH Dalle, N Bleyzac, B Neven, ...
Therapeutic drug monitoring 34 (2), 198-208, 2012
Liquid chromatography–tandem mass spectrometry assay of reduced and oxidized glutathione and main precursors in mice liver
J Bouligand, A Deroussent, A Paci, J Morizet, G Vassal
Journal of chromatography B 832 (1), 67-74, 2006
Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance …
V Minard-Colin, JL Ichante, L Nguyen, A Paci, D Orbach, C Bergeron, ...
European Journal of Cancer 48 (15), 2409-2416, 2012
High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up
S Mauclere-Denost, S Leboulleux, I Borget, A Paci, J Young, A Al Ghuzlan, ...
European journal of endocrinology 166 (2), 261-268, 2012
Prognostic markers of survival after combined mitotane-and platinum-based chemotherapy in metastatic adrenocortical carcinoma
P Malandrino, A Al Ghuzlan, M Castaing, J Young, B Caillou, JP Travagli, ...
Endocrine-Related Cancer 17 (3), 797, 2010
Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients
V Launay-Vacher1ACDE, H Izzedine1AD, JB Rey2ABC, O Rixe3AD, ...
Med Sci Monit 10 (5), 212, 2004
The system can't perform the operation now. Try again later.
Articles 1–20